Gene · 5928
Papers2,308
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,308
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12-Year Retrospective Cohort Study of 3487 Consecutive Patients. | Ann Gastroenterol Surg | 2026 | 42395139 | PubTator, text mining | PubMed |
| Pharmacologic inhibition of RBBP4/p300-mediated homologous recombination activity enhances glioblastoma sensitivity to temozolomide. | Neurooncol Adv | 2026 | 42291750 | PubTator, text mining | PubMed |
| Paradoxical hyperprogressive disease in MSI-high intrahepatic cholangiocarcinoma treated with pembrolizumab. | Clin J Gastroenterol | 2026 | 42289019 | PubTator, text mining | PubMed |
| Assessment of Anticancer Effect of Rhodium Nanoparticle-based Photodynamic Therapy via Protein-Protein Interaction Network Analysis. | J Lasers Med Sci | 2026 | 42233111 | PubTator, text mining | PubMed |
| Rapid On-Site Next-Generation Sequencing: An Alternative to Single-Gene and Send-Out Testing in Non-Small Cell Lung Cancer and Colorectal Cancer in a Community Pathology Laboratory Setting. | J Mol Diagn | 2026 | 42214484 | PubTator, text mining | PubMed |
| Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study. | Front Oncol | 2026 | 42200018 | PubTator, text mining | PubMed |
| mTORC2 Phosphorylation of GSDME-N Drives Cullin4B-Mediated Proteasomal Degradation to Suppress Pyroptosis and Confer Radioresistance in Small Cell Lung Cancer. | Adv Sci (Weinh) | 2026 | 42199156 | PubTator, text mining | PubMed |
| Age-stratified impact of microsatellite instability on lymph node positivity and survival in stage I-III colon cancer. | J Geriatr Oncol | 2026 | 42166995 | PubTator, text mining | PubMed |
| Circulating Tumor DNA and Precision Biomarkers in Colorectal Cancer: Implications for Diagnosis, Monitoring, and Management of Advanced Disease. | J Gastroenterol Hepatol | 2026 | 42150752 | PubTator, text mining | PubMed |
| Exceptional Response to Lenvatinib plus Pembrolizumab after Pembrolizumab Failure in MLH1-Methylated Deficient Mismatch Repair/Microsatellite Instability-High Endometrial Cancer: A Case Report. | Case Rep Oncol | 2026 | 42136687 | PubTator, text mining | PubMed |
| Beyond the image: achieving complete pathologic response in MSI-high metastatic colon cancer despite persistent PET activity. | Int J Surg Case Rep | 2026 | 42130570 | PubTator, text mining | PubMed |
| Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multiomics Platform. | Clin Cancer Res | 2026 | 41995725 | PubTator, text mining | PubMed |
| EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. | Int J Mol Sci | 2026 | 41977448 | PubTator, text mining | PubMed |
| Pembrolizumab plus chemotherapy following lack of response to nivolumab-based therapy in MSI-High/dMMR advanced gastric cancer: a case report. | Int Cancer Conf J | 2026 | 41929547 | PubTator, text mining | PubMed |
| RNA binding protein Musashi1 interacts with the viral genomic RNA and restricts SARS-CoV-2 infection by repressing translation. | Nucleic Acids Res | 2026 | 41914497 | PubTator, text mining | PubMed |
| Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma. | Oncoimmunology | 2026 | 41913413 | PubTator, text mining | PubMed |
| Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. | Oncologist | 2026 | 41913057 | PubTator, text mining | PubMed |
| CXCL12 and eotaxin are independent prognostic serum biomarkers in gastric cancer. | Sci Rep | 2026 | 41906027 | PubTator, text mining | PubMed |
| Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1/tissue-resident NK cell differentiation. | Nat Commun | 2026 | 41896575 | PubTator, text mining | PubMed |
| Reversible aggregation-redispersion of Cu sites in Cu/CeO2 catalysts with unlocked hydrogenation activity. | Sci Adv | 2026 | 41894513 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5928/papers?page=2